CDK12: A Potent Target and Biomarker for Human Cancer Therapy

Cells

Shujing Liang¹  Lifang Hu¹  Airong Qian¹  Zixiang Wu¹  Xia Xu¹  Zhihao Chen¹  Shuyu Liu¹ 

[1] Laboratory for Bone Metabolism, Xi’an Key Laboratory of Special Medicine and Health Engineering, Northwestern Polytechnical University, Xi’an 710072, China;

关键词: cyclin-dependent kinase 12;    gene transcription;    cell cycle;    cell proliferation;    DNA damage response;    cancer therapy;   

DOI  :  10.3390/cells9061483

来源: DOAJ

【 摘 要 】

Cyclin-dependent kinases (CDKs) are a group of serine/threonine protein kinases and play crucial roles in various cellular processes by regulating cell cycle and gene transcription. Cyclin-dependent kinase 12 (CDK12) is an important transcription-associated CDK. It shows versatile roles in regulating gene transcription, RNA splicing, translation, DNA damage response (DDR), cell cycle progression and cell proliferation. Recently, increasing evidence demonstrates the important role of CDK12 in various human cancers, illustrating it as both a biomarker of cancer and a potential target for cancer therapy. Here, we summarize the current knowledge of CDK12, and review the research advances of CDK12′s biological functions, especially its role in human cancers and as a potential target and biomarker for cancer therapy.

【 授权许可】

Unknown